Bill joined Evelo in 2015 as vice president of intellectual property. Prior to joining Evelo, DeVaul was Deputy Chief Intellectual Property Officer at Cubist Pharmaceuticals. While at Cubist, Bill led the intellectual property team and managed corporate litigation. Bill managed several Paragraph IV litigations and Inter Partes Reviews involving the patents protecting Cubicin®, a $1B annual revenue IV drug. Bill’s team obtained significant protection for additional products including Cubicin®, Zerbaxa®, Sivextro®, Dificid® and Entereg®. Bill was also the lead attorney on numerous deals, including licensing and collaborations, co-promotion agreements and acquisitions of private and public companies. Bill is a graduate of Boston University School of Law and holds a degree in biochemistry from Columbia University.